Excella GmbH & Co. KG, founded in 1972, is a Germany-based company that has been a key player in the pharmaceutical sector for over 35 years. The company specializes in providing premium APIs and finished dosage forms, with recent investments directing their focus towards high containment products, including OEB5, and an all-inclusive service approach. Excella caters to the needs of the generic industry and also manufactures life cycle end products for big pharma, while simultaneously developing processes for innovative APIs and novel solid dosage forms. The company offers a comprehensive range of services, from early product development and registration support to state-of-the-art manufacturing. Notably, Excella's Feucht site has maintained FDA and other regulatory agencies' compliance since 1983 and is Safebridge certified, ensuring the highest quality standards. With its established history, diverse product offerings, and commitment to regulatory compliance, Excella presents a compelling investment opportunity for venture capitalists seeking to support advancements in the pharmaceutical industry.
There is no investment information
No recent news or press coverage available for Excella GmbH & Co. KG.
We care about your data, and we'd love to use cookies make your experience better.
